EMPA-REG OUTCOME Trial: as published in
The New England Journal of Medicine1
PATIENTS STUDIED HAD:
Evidenced by coronary artery disease, peripheral artery disease, or a history of myocardial infarction or stroke
TYPE 2 DIABETES
A1C baseline of ≥7%-≤10%
Patients were randomized to receive:
JARDIANCE 10 mg
JARDIANCE 25 mg
Clinical findings were achieved on top of cardiovascular and type 2 diabetes
standard of care medications*
TYPE 2 DIABETES MEDICATIONS
Investigators were encouraged to manage CV risk factors and blood glucose by actively adjusting all medications in order to achieve appropriate treatment goals in all treatment groups.
*Percentages reflect medications taken at baseline. Type 2 diabetes medications were kept stable for the first 12 weeks.
ACEIs=angiotensin-converting enzyme inhibitors; ARBs=angiotensin ll receptor blockers; CV=cardiovascular.